All Stories

  1. The Perioperative Use of Levosimendan as a Means of Optimizing the Surgical Outcome in Patients with Severe Heart Insufficiency Undergoing Cardiac Surgery
  2. Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy
  3. Global initiative for chronic obstructive lung disease (GOLD) recommendations: strengths and concerns for future needs
  4. Lung Metastatectomy: Can Laser-Assisted Surgery Make a Difference?
  5. Can Chest Ultrasound Replace Chest X-ray in Thoracic Surgery?
  6. RELIght: A two‐year REal‐LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response
  7. Blood eosinophils in COPD: friend or foe?
  8. Updated simplified approach of pharmacological treatment of stable COPD: Do common co-morbidities have a role?
  9. Depression Levels Influence the Rate of Asthma Exacerbations in Females
  10. Device use errors among patients with asthma and COPD and the role of training: a real-life study
  11. Bronchoscopic diagnosis and treatment of endobronchial carcinoid: case report and review of the literature
  12. PROMS and FEV1 as predictors of AECOPD
  13. Prevalence, distribution and clinical significance of joints, muscles and bones in sarcoidosis: an 18F-FDG-PET/CT study
  14. Sirtuin 1: Endocan and Sestrin 2 in Different Biological Samples in Patients with Asthma. Does Severity Make the Difference?
  15. Pharmacological treatment of stable COPD: need for a simplified approach
  16. Asthma‐chronic obstructive pulmonary disease overlap: Diagnostic stability and inflammatory characteristics
  17. Inflammatory profile in optimally treated patients with adult versus early-onset asthma
  18. TERT/TERC mutations in a Greek cohort of suspected genetic pulmonary fibrosis patients
  19. Mycophenalate Mofetil as a corticosteroid- sparing agent in patients with sarcoidosis.
  20. The effects of pulmonary rehabilitation in patients with Combined Pulmonary Fibrosis and Emphysema (CPFE)
  21. Late onset asthma: A distinct phenotype
  22. Serum Surfactant Protein Levels in Patients Admitted to the Hospital with Acute COPD Exacerbation
  23. Emphysematous Phenotype is Characterized by Low Blood Eosinophils: A Cross-Sectional Study
  24. Decreased Serum Sirtuin-1 in COPD
  25. Serum periostin in patients hospitalized for COPD exacerbations
  26. Activin A and follistatin in patients with asthma. Does severity make the difference?
  27. Sputum interleukin‐13 as a biomarker for the evaluation of asthma control
  28. Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation
  29. Clinical, functional and inflammatory characteristics in patients with paucigranulocytic asthma
  30. Predictors of future exacerbation risk in patients with asthma
  31. Sputum interleukin-13 as a biomarker for the evaluation of asthma control
  32. Persistent airflow obstruction in patients with asthma: Characteristics of a distinct clinical phenotype
  33. Predictors of exacerbations in asthma
  34. Activin-A BAL levels and Immunochemistry for activin A receptors in patients with asthma
  35. Periostin as a biomarker in patients with asthma: Associations with eosinophilia and Th2 response
  36. Serum periostin in patients hospitalized for COPD exacerbations
  37. Pulmonary alveolar proteinosis: time to shift?
  38. Sputum interleukin (IL)-13 as a biomarker for the evaluation of asthma control
  39. Sputum and BAL Clara cell secretory protein and surfactant protein D levels in asthma
  40. Increased Levels of Osteopontin in Sputum Supernatant in Patients With COPD
  41. Long-Term Inhaled Granulocyte Macrophage–Colony-Stimulating Factor in Autoimmune Pulmonary Alveolar Proteinosis: Effectiveness, Safety, and Lowest Effective Dose
  42. Levels of prostaglandin E2 and Cysteinyl‐leukotrienes in sputum supernatant of patients with asthma: the effect of smoking
  43. Noninvasive evaluation of airway inflammation in patients with severe asthma